Maureen A O’leary
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Maureen A O’leary has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Betty Kirkwood
Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK
1 shared publicationCaitlin Shannon
Engender Health, New York, New York, USA
1 shared publication- Danielle R. Reed
Monell Chemical Senses Center, Philadelphia, PA 19104, USA
1 shared publication Gyan Thomas
Kintampo Health Research Centre, Kintampo, Ghana
1 shared publicationKaren Edmond
School of Paediatrics and Child Health, University of Western Australia, Crawley, Western Australia, Australia
1 shared publicationLisa Hurt
Institute of Primary Care and Public Health, School of Medicine, Cardiff University, Cardiff, UK
1 shared publication
Latest Publications
- Open Access
- 1 January 2023
- Published by Oxford University Press (OUP) in Chemical Senses
- Vol. 48
Proof-of-concept: SCENTinel 1.1 rapidly discriminates COVID-19-related olfactory disorders
It is estimated that 20%–67% of those with COVID-19 develop olfactory disorders, depending on the SARS-CoV-2 variant. However, there is an absence of quick, population-wide olfactory tests to screen for olfactory disorders. The purpose of this study was to provide a proof-of-concept that SCENTinel 1.1, a rapid, inexpensive, population-wide olfactory test, can discriminate between anosmia (total smell loss), hyposmia (reduced sense of smell), parosmia (distorted odor perception), and phantosmia (odor sensation without a source). Participants were mailed a SCENTinel 1.1 test, which measures odor detection, intensity, identification, and pleasantness, using one of 4 possible odors. Those who completed the test (N = 287) were divided into groups based on their self-reported olfactory function: quantitative olfactory disorder only (anosmia or hyposmia, N = 135), qualitative olfactory disorder only (parosmia and/or phantosmia; N = 86), and normosmia (normal sense of smell; N = 66). SCENTinel 1.1 accurately discriminates quantitative olfactory disorders, qualitative olfactory disorders, and normosmia groups. When olfactory disorders were assessed individually, SCENTinel 1.1 discriminates between hyposmia, parosmia, and anosmia. Participants with parosmia rated common odors less pleasant than those without parosmia. We provide proof-of-concept that SCENTinel 1.1, a rapid smell test, can discriminate quantitative and qualitative olfactory disorders, and is the only direct test to rapidly discriminate parosmia.
- 1 January 2023
- Published by Oxford University Press (OUP) in Chemical Senses
- Vol. 48
Open AccessProof-of-concept: SCENTinel 1.1 rapidly discriminates COVID-19-related olfactory disorders
It is estimated that 20%–67% of those with COVID-19 develop olfactory disorders, depending on the SARS-CoV-2 variant. However, there is an absence of quick, population-wide olfactory tests to screen for olfactory disorders. The purpose of this study was to provide a proof-of-concept that SCENTinel 1.1, a rapid, inexpensive, population-wide olfactory test, can discriminate between anosmia (total smell loss), hyposmia (reduced sense of smell), parosmia (distorted odor perception), and phantosmia (odor sensation without a source). Participants were mailed a SCENTinel 1.1 test, which measures odor detection, intensity, identification, and pleasantness, using one of 4 possible odors. Those who completed the test (N = 287) were divided into groups based on their self-reported olfactory function: quantitative olfactory disorder only (anosmia or hyposmia, N = 135), qualitative olfactory disorder only (parosmia and/or phantosmia; N = 86), and normosmia (normal sense of smell; N = 66). SCENTinel 1.1 accurately discriminates quantitative olfactory disorders, qualitative olfactory disorders, and normosmia groups. When olfactory disorders were assessed individually, SCENTinel 1.1 discriminates between hyposmia, parosmia, and anosmia. Participants with parosmia rated common odors less pleasant than those without parosmia. We provide proof-of-concept that SCENTinel 1.1, a rapid smell test, can discriminate quantitative and qualitative olfactory disorders, and is the only direct test to rapidly discriminate parosmia.
- Open Access
- 13 October 2016
- Published by BMJ in Archives of Disease in Childhood
- Vol. 102 (2) , 145-151
Neonatal vaccination of low birthweight infants in Ghana
Objectives Global vaccination policy advocates for identifying and targeting groups who are underserved by vaccination to increase equity and uptake. We investigated whether birth weight and other factors are determinants of neonatal BCG vaccination in order to identify infants underserved by vaccination. Methods We used logistic regression to calculate adjusted ORs (AORs) for the association between birth weight (categorised as non-low birth weight (NLBW) (≥2.50 kg) and low birth weight (LBW) (2–2.49 kg, 1.50–1.99 kg and Results There was a strong dose–response relationship between LBW and not receiving BCG in the neonatal period (p-trendConclusions LBW is a risk factor for neonatal under-vaccination, even for facility-born infants. Ensuring vaccination at facility births would substantively improve timing and equitable BCG vaccination.
- 13 October 2016
- Published by BMJ in Archives of Disease in Childhood
- Vol. 102 (2) , 145-151
Open AccessNeonatal vaccination of low birthweight infants in Ghana
Objectives Global vaccination policy advocates for identifying and targeting groups who are underserved by vaccination to increase equity and uptake. We investigated whether birth weight and other factors are determinants of neonatal BCG vaccination in order to identify infants underserved by vaccination. Methods We used logistic regression to calculate adjusted ORs (AORs) for the association between birth weight (categorised as non-low birth weight (NLBW) (≥2.50 kg) and low birth weight (LBW) (2–2.49 kg, 1.50–1.99 kg and Results There was a strong dose–response relationship between LBW and not receiving BCG in the neonatal period (p-trendConclusions LBW is a risk factor for neonatal under-vaccination, even for facility-born infants. Ensuring vaccination at facility births would substantively improve timing and equitable BCG vaccination.